The AKT inhibitor ARQ-092 led to the remission of a cancer in a patient with Proteus Syndrome carrying an AKT1 mutation, and is currently undergoing clinical evaluation in PROS [73]. The gene discussed is AKT1; the disease is Proteus syndrome.